System Entry • 4/5/2026
CJC-1295 With DAC vs Without DAC: Half-Life and Research Design
Drug Affinity Complex (DAC) extends half-life of GHRH analogs. What that means for dosing frequency in animal studies versus no-DAC variants—conceptual overview only.
### DAC chemistry
**Drug Affinity Complex (DAC)** conjugation to CJC-1295 binds serum albumin, slowing clearance and extending **circulating half-life** compared with **no-DAC** CJC-1295 in pharmacokinetic studies.
### Research implications (conceptual)
Longer half-life can mean fewer administrations in animal models—but also different pulse physiology vs short-acting GHRH fragments. Study design depends on endpoint: acute GH pulse vs sustained IGF-1 elevation.
### No protocols
We do not provide doses or schedules. Consult the literature and institutional IACUC or equivalent oversight.
### RUO
Laboratory research only.
*Both CJC-1295 (no DAC) and CJC-1295 with DAC are available for research at peptide limited.*
